Suppr超能文献

隐匿性乙型肝炎病毒感染

Occult hepatitis B virus infection.

作者信息

Allain Jean-Pierre

机构信息

Division of Transfusion Medicine, Department of Haematology, University of Cambridge, Cambridge Blood Centre, Long Road, Cambridge CR2 2PT, UK.

出版信息

Transfus Clin Biol. 2004 Feb;11(1):18-25. doi: 10.1016/j.tracli.2003.11.007.

Abstract

The detection of HBV DNA without HBsAg with or without the presence of HBV antibodies outside the acute phase window period defines occult HBV infection. This condition has been described in hepatocellular carcinoma (HCC), chronic hepatitis B, healthy HBV carriage and recovered infection, chronic hepatitis C and individuals without serological markers of HBV. The frequency of the diagnosis depends on the relative sensitivity of both HBsAg and HBV DNA assays. It also depends on the prevalence of HBV infection in the population. Occult HBV in blood donors has a wide range of potential origins within the natural history of the infection. It may originate from recovered infections with anti-HBs and persistent, low-level, viral replication, escape mutants undetected by the HBsAg assays or healthy chronic carriage. The last situation is mostly found with anti-HBc only. Over time, antibody markers may become undetectable leaving HBV DNA as the only marker of the infection. In all cases, the viral load is low, mostly below 10(4) IU/ml, often below 100 IU/ml. At these levels, nucleic acid testing (NAT) in pools is likely to be largely ineffective. Is occult HBV transmissible by transfusion? Carriers of anti-HBs or anti-HBc only were shown infectious in immunosuppressed organ or bone marrow transplant recipients. In immunocompetent recipients, there is no evidence that anti-HBs-containing components are infectious, even in low titre. Donations carrying anti-HBc only and HBV DNA can be infectious and this is a threat where anti-HBc is not screened. Anti-HBc screening identifies most occult HBV infection but not all. HBV NAT needs either extreme sensitivity or to be performed on individual donations to eliminate HBV DNA-containing units.

摘要

在急性期窗口期之外检测到无乙肝表面抗原(HBsAg)且伴有或不伴有乙肝病毒(HBV)抗体的HBV DNA,即定义为隐匿性HBV感染。这种情况已在肝细胞癌(HCC)、慢性乙型肝炎、健康HBV携带者和康复感染、慢性丙型肝炎以及无HBV血清学标志物的个体中有所描述。诊断的频率取决于HBsAg和HBV DNA检测的相对灵敏度。它还取决于人群中HBV感染的流行率。献血者中的隐匿性HBV在感染的自然史中有多种潜在来源。它可能源于伴有抗-HBs的康复感染以及持续性、低水平的病毒复制、HBsAg检测未检测到的逃逸突变体或健康慢性携带者。最后一种情况大多仅见于抗-HBc阳性者。随着时间的推移,抗体标志物可能无法检测到,仅留下HBV DNA作为感染的唯一标志物。在所有情况下,病毒载量都很低,大多低于10⁴ IU/ml,通常低于100 IU/ml。在这些水平下,混合样本的核酸检测(NAT)可能在很大程度上无效。隐匿性HBV可通过输血传播吗?仅抗-HBs或抗-HBc携带者在免疫抑制的器官或骨髓移植受者中显示具有传染性。在免疫功能正常的受者中,没有证据表明含抗-HBs的成分具有传染性,即使是低滴度。仅携带抗-HBc和HBV DNA的献血可能具有传染性,在未筛查抗-HBc的情况下这是一种威胁。抗-HBc筛查可识别大多数隐匿性HBV感染,但并非全部。HBV NAT需要极高的灵敏度或对单个献血样本进行检测,以消除含有HBV DNA的单位。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验